Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo(1,2-a)pyridin-3-yl)methylamino)-4-(4-fluorophenyl)thiazole-5-carbonitrile
2. Glpg1690
1. 1628260-79-6
2. Glpg-1690
3. Glpg1690
4. 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile
5. Ziritaxestat [usan]
6. Glpg-1690(ziritaxestat)
7. Chembl3828074
8. G451990
9. I02418v13w
10. G-451990
11. 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl]-methylamino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile
12. 5-thiazolecarbonitrile, 2-((2-ethyl-6-(4-(2-(3-hydroxy-1-azetidinyl)-2-oxoethyl)-1-piperazinyl)-8-methylimidazo(1,2-a)pyridin-3-yl)methylamino)-4-(4-fluorophenyl)-
13. Ziritaxestatn
14. Ziritaxestat (usan/inn)
15. Ziritaxestat [inn]
16. Ziritaxestat (glpg1690)
17. Gtpl9561
18. Schembl16051264
19. Unii-i02418v13w
20. Bcp20895
21. Ex-a1646
22. Bdbm50187686
23. Mfcd31544330
24. S8895
25. Who 11017
26. Cs-7634
27. Db15403
28. Sb19736
29. Compound 11 [pmid: 28414242]
30. Ac-36149
31. Hy-101772
32. J3.652.431f
33. D11844
34. A902613
35. Q23075652
36. 2-((2-ethyl-6-(4-(2-(3-hydroxyazetidin-1-yl)-2-oxoethyl)piperazin-1-yl)-8-methylimidazo[1,2-a]pyridin-3-yl)(methyl)amino)-4-(4-fluorophenyl)thiazole-5-carbonitrile;glpg1690
37. 42-ethyl-14-fluoro-83-hydroxy-3,48-dimethyl-7-oxo-3-aza-4(3,6)-imidazo(1,2-a)pyridina-5(1,4)-piperazina-2(4,2)-(1,3)thiazola-8(1)-azetidina-1(1)-benzenaoctaphane-25-carbonitrile
| Molecular Weight | 588.7 g/mol |
|---|---|
| Molecular Formula | C30H33FN8O2S |
| XLogP3 | 4.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 7 |
| Exact Mass | 588.24312166 g/mol |
| Monoisotopic Mass | 588.24312166 g/mol |
| Topological Polar Surface Area | 133 Ų |
| Heavy Atom Count | 42 |
| Formal Charge | 0 |
| Complexity | 995 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
100
PharmaCompass offers a list of Ziritaxestat API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Ziritaxestat manufacturer or Ziritaxestat supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Ziritaxestat manufacturer or Ziritaxestat supplier.
PharmaCompass also assists you with knowing the Ziritaxestat API Price utilized in the formulation of products. Ziritaxestat API Price is not always fixed or binding as the Ziritaxestat Price is obtained through a variety of data sources. The Ziritaxestat Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Ziritaxestat manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Ziritaxestat, including repackagers and relabelers. The FDA regulates Ziritaxestat manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Ziritaxestat API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Ziritaxestat supplier is an individual or a company that provides Ziritaxestat active pharmaceutical ingredient (API) or Ziritaxestat finished formulations upon request. The Ziritaxestat suppliers may include Ziritaxestat API manufacturers, exporters, distributors and traders.
Ziritaxestat Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Ziritaxestat GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Ziritaxestat GMP manufacturer or Ziritaxestat GMP API supplier for your needs.
A Ziritaxestat CoA (Certificate of Analysis) is a formal document that attests to Ziritaxestat's compliance with Ziritaxestat specifications and serves as a tool for batch-level quality control.
Ziritaxestat CoA mostly includes findings from lab analyses of a specific batch. For each Ziritaxestat CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Ziritaxestat may be tested according to a variety of international standards, such as European Pharmacopoeia (Ziritaxestat EP), Ziritaxestat JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Ziritaxestat USP).
